The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Jason Gotlib

Division of Hematology

Stanford University Medical Center

Palo Alto



Name/email consistency: high



  • Division of Hematology, Stanford University Medical Center, Palo Alto, USA. 2012
  • Division of Hematology, Department of Medicine, Stanford University School of Medicine/Stanford Cancer Center, Stanford, California. 2004 - 2011
  • Stanford Cancer Center, Stanford University School of Medicine, 875 Blake Wilbur Drive, Room 2327B, USA. 2006


  1. World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management. Gotlib, J. Am. J. Hematol. (2012) [Pubmed]
  2. World health organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management. Gotlib, J. Am. J. Hematol. (2011) [Pubmed]
  3. Eosinophilic myeloid disorders: new classification and novel therapeutic strategies. Gotlib, J. Curr. Opin. Hematol. (2010) [Pubmed]
  4. A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. Gotlib, J., Lavori, P., Quesada, S., Stein, R.S., Shahnia, S., Greenberg, P.L. Am. J. Hematol. (2009) [Pubmed]
  5. On being metachromatic: mystique and misunderstanding in mastocytosis. Gotlib, J. Am. J. Hematol. (2009) [Pubmed]
  6. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Gotlib, J., Cools, J. Leukemia (2008) [Pubmed]
  7. KIT mutations in mastocytosis and their potential as therapeutic targets. Gotlib, J. Immunol. Allergy. Clin. North. Am (2006) [Pubmed]
  8. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. Gotlib, J., Cross, N.C., Gilliland, D.G. Best. Pract. Res. Clin. Haematol (2006) [Pubmed]
  9. Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. Gotlib, J. Curr. Hematol. Rep. (2005) [Pubmed]
  10. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Gotlib, J., Berubé, C., Growney, J.D., Chen, C.C., George, T.I., Williams, C., Kajiguchi, T., Ruan, J., Lilleberg, S.L., Durocher, J.A., Lichy, J.H., Wang, Y., Cohen, P.S., Arber, D.A., Heinrich, M.C., Neckers, L., Galli, S.J., Gilliland, D.G., Coutré, S.E. Blood (2005) [Pubmed]
  11. Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. Gotlib, J. Acta Haematol. (2005) [Pubmed]
  12. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Gotlib, J., Cools, J., Malone, J.M., Schrier, S.L., Gilliland, D.G., Coutré, S.E. Blood (2004) [Pubmed]
WikiGenes - Universities